Skip to main content
OpenTrials
Completed

NCT Number: NCT02279953

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

EE001, Tallinn, Estonia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient has achieved either partial (some symptoms of a MDE are present but full criteria are not met) or full remission of major depressive disorder (MDD), diagnosed according to DSM-IV-TR™.
  • The patient has HAMD-17 total score ≤10.
  • The patient has received SSRI monotherapy for the MDE from which the patient is currently in full or partial remission for ≥12 weeks at licensed doses and been on stable dose ≥8 weeks prior to Screening Visit.
  • The patient has ≥50% response to current SSRI treatment (Antidepressant Treatment Response Questionnaire [ATRQ]).
  • The patient has a PDQ-D total score >25.
  • The patient is a man or woman, aged ≥18 and ≤65 years.

Exclusion criteria

  • The patient has a score ≥70 on the DSST (numbers of correct symbols) at the Baseline Visit.
  • The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient has a history of lack of response to previous adequate treatment with vortioxetine.
  • The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using Mini International Neuropsychiatric Interview (MINI).
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of the depressive episode from which the patient is currently in full or partial remission (DSM-IV-TR™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol-defined inclusion and exclusion criteria may apply.

Treatment and study plan

Vortioxetine 10-20 mg

Drug

Other names: Brintellix®, Lu AA21004

Placebo

Drug

SSRI

Drug

escitalopram, citalopram or sertraline

Primary outcomes

  1. Change in Digit Symbol Substitution Test (DSST): number of correct symbols

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])

    Time frame: Baseline to Week 8

  2. Change in Trail Making Test (TMT) score: TMT-A; speed of processing

    Time frame: Baseline to Week 8

  3. Change in TMT score: TMT-B; executive functioning

    Time frame: Baseline to Week 8

  4. Change in reaction time score: Choice Reaction Time (CRT); attention

    Time frame: Baseline to Week 8

  5. Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed

    Time frame: Baseline to Week 8

  6. Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning

    Time frame: Baseline to Week 8

  7. Change in STROOP: congruent score; speed of processing

    Time frame: Baseline to Week 8

  8. Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score

    Time frame: Baseline to Week 8

  9. Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score

    Time frame: Baseline to Week 8

  10. Change in Clinical Global Impression - Severity of Illness (CGI-S)

    Time frame: Baseline to Week 8

  11. Clinical Global Impression - Global Improvement (CGI-I) score

    Time frame: Week 8

  12. Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score

    Time frame: Baseline to Week 8

  13. Number of adverse events

    Time frame: Baseline to Week 12

  14. Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)

    Time frame: Baseline to Week 8

Sponsors and collaborators

Lead sponsor

H. Lundbeck A/S

Industry

Registry information

Official study title

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Oct 31, 2014
Registry last updated
May 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.